Vigabatrin 500 MG Oral Tablet [Sabril]

Known as: Sabril 500 MG Oral Tablet, VIGABATRIN 500 mg ORAL TABLET, FILM COATED [SABRIL] 
 
National Institutes of Health

Related topics

Related topics

10 relations
Magnesium stearateOral TabletPolyethylene GlycolsPovidone
(More)

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Sabril® registry 5-year results: Characteristics of adult patients treated with vigabatrin
Vigabatrin (Sabril®), approved in the US in 2009, is currently indicated as adjunctive therapy for refractory complex partial… (More)
Is this relevant?
2016
2016
Which children receive vigabatrin? Characteristics of pediatric patients enrolled in the mandatory FDA registry
Vigabatrin (Sabril®) is an antiepileptic drug (AED) currently indicated in the US as a monotherapy for patients 1month to 2years… (More)
Is this relevant?
2012
2012
PND44 Cost-Utility Analysis and Cost-Minimisation Analysis of Sabril® (Vigabatrin) in Drug-Resistant Epilepsy From Payer's Perspective in Poland
 
Is this relevant?
2011
2011
Screening for vigabatrin (Sabril ®) retinal toxicity in children.
 
Is this relevant?
2000
2000
Der derzeitige Stellenwert von Vigabatrin (Sabril®) in der Epilepsiebehandlung - Ergebnisse einer Konsenskonferenz*
 
Is this relevant?
1997
1997
Obstructive sleep apnoea following rapid weight gain secondary to treatment with vigabatrin (Sabril®)
A case of a patient with medically intractable epilepsy, who developed obstructive sleep apnoea (OSA), and an increase in seizure… (More)
Is this relevant?
1997
1997
Multicentre clinical evaluation of vigabatrin (Sabril®) in mild to moderate partial epilepsies
Vigabatrin (VGB) has been shown through several studies to be safe and effective as add-on therapy, particularly for the… (More)
  • table 1
  • table 2
  • figure 1
  • table 3
  • figure 2
Is this relevant?